Dyne Therapeutics has been granted a patent for a composition that includes complexes of an anti-transferrin receptor antibody covalently linked to oligonucleotides. The antibody specifically binds to muscle cells and the oligonucleotides promote the expression of a functional dystrophin protein. The composition has the potential to treat genetic disorders such as Duchenne muscular dystrophy. GlobalData’s report on Dyne Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Dyne Therapeutics, Antibody-conjugate nanoparticles was a key innovation area identified from patents. Dyne Therapeutics's grant share as of September 2023 was 8%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for complexes linking muscle-targeting agent to oligonucleotide
A recently granted patent (Publication Number: US11771776B2) describes a composition that includes complexes consisting of an anti-transferrin receptor (TfR) antibody covalently linked to one or more oligonucleotides. The antibody is a Fab and has specific amino acid sequences for its heavy and light chains. Each anti-TfR antibody in the complexes is on average linked to 1 to 3 oligonucleotides. The oligonucleotide in the composition induces dystrophin exon 51 skipping, which is a process that can be used to treat certain genetic disorders.
The patent also mentions various characteristics and features of the composition. For example, the heavy chain of the antibody may have an N-terminal pyroglutamate. The equilibrium dissociation constant (KD) of the antibody's binding to the transferrin receptor falls within a range from 10-11 M to 10-6 M. The oligonucleotide in the composition is 15-35 nucleotides long and contains a region of complementarity to a dystrophin RNA, which is 12-35 nucleotides long. Additionally, the oligonucleotide may have a region of complementarity to specific target sequences of other oligonucleotides listed in the patent.
The composition may also include oligonucleotides with specific nucleotide sequences, where thymine bases (T's) can be optionally replaced with uracil bases (U's) and vice versa. Modified nucleosides can be present in the oligonucleotide as well. One specific type of oligonucleotide mentioned is a phosphorodiamidate morpholino oligomer.
The patent also describes a method of using the composition to induce dystrophin exon 51 skipping in muscle cells of a subject. The method involves administering the composition to the subject, who can be human or a cynomolgus (a type of monkey). The subject may have a frameshift mutation in their dystrophin pre-mRNA and be amenable to dystrophin exon 51 skipping. The administration of the complex can be done intravenously. The method is particularly relevant for subjects with Duchenne muscular dystrophy.
In summary, the granted patent outlines a composition consisting of complexes of an anti-transferrin receptor antibody and oligonucleotides that induce dystrophin exon 51 skipping. The patent also covers various characteristics of the composition and describes a method of using it to treat certain genetic disorders, particularly Duchenne muscular dystrophy.
To know more about GlobalData’s detailed insights on Dyne Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
